Two Directors at ConocoPhillips sold/bought 10,407 shares at between 0.000USD and 120.070USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
NewtekOne, Inc. Declares Dividends on Common Stock and Series B Preferred Shares BOCA RATON, Fla., March 13, 2026 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: NEWT) announced that its Board of Directors declared a quarterly cash dividend of $0.19 per share on the Company’s outstanding common stock. The dividend is payable on April 1, 2026, to shareholders of record as of March 24, 2026. The Company’s Board of Directors also declared a dividend on the Company’s outstanding 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (the “Preferred Shares”) (NASDAQ: NEWTP) ...
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that it will implement a 1-for-14 reverse stock split of the issued shares of the company’s common stock, effective at 5:00 p.m. Eastern Time on March 13, 2026. The reverse stock split was approved by the company’s stockholders at the company’s Special Meeting of Stockholders held on February 23, 2...
The Lovesac Company Announces Fourth Quarter and Fiscal 2026 Conference Call Date STAMFORD, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that its fourth quarter and fiscal 2026 financial results will be released before market open on Thursday, March 26, 2026. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (internatio...
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth...
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum. Details regarding Lifecore’s participation are as follows: 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum Details: Mr. Josephs will be a featured speaker in a fireside chat...
Newtek Bank, N.A. Introduces the Newtek Seven Day Business Loan™ BOCA RATON, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (NASDAQ: NEWT) (“NewtekOne”) announced that its bank subsidiary, Newtek Bank, National Association (the “Bank”), launched the Newtek Seven Day Business Loan™: business loans of up to $350,000 funded to approved borrowers within seven days of a complete loan application. The Newtek Seven Day Business Loan is structured over a ten-year repayment period, with no balloon payment risk, and a total borrowing cost – including interest and fees – that we believe is...
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 Preclinical development and IND enabling studies for PRT13722, highly-selective oral KAT6A degrader underway, and the Company intends to file the IND for PRT13722 in mid-2026 with Phase 1 study initiation anticipated in the 2nd half...
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026 Webcast Scheduled for Monday, March 16 at 8:30 a.m. Eastern CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and transition period ended December 31, 2025, on Monday, March 16, 2026, before the market opens. At 8:30 a.m. Eastern Time t...
Progyny, Inc. Executives to Participate in Upcoming Investor Conferences NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. At the Leerink Partners Global Healthcare Conference, Mark Livingston, Chief Financial Officer, will partic...
Occidental Announces Total Consideration for its Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced the consideration payable in respect of its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its Zero Coupon Senior Notes due 2036 (the “0.000% 2036 Notes”), 6.125% Senior Notes due 2031 (the “6.125% 2031 Notes”), 6.625% Senior Notes due 2030 (the “6.625% 2030 Notes”), 7.200% Debentures due 2029 (the “7.200% 2029 Debentures”) and 7.950% D...
Occidental Announces Early Tender Results and Upsize in Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced the early tender results, as set forth in the table below, of its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its Zero Coupon Senior Notes due 2036 (the “0.000% 2036 Notes”), 6.125% Senior Notes due 2031 (the “6.125% 2031 Notes”), 6.625% Senior Notes due 2030 (the “6.625% 2030 Notes”), 7.200% Debentures due 2029 (the “7.200% 2...
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials CHASKA, Minn. and BOSTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clini...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.